Resources

Worldwide, 71 million people are infected with hepatitis C virus (HCV), which, without treatment, can lead to liver failure or hepatocellular carcinoma. HCV co-infection increases liver- and AIDS-related morbidity and mortality among HIV-positive people, despite ART. A 12-week course of HCV direct-acting antivirals (DAAs) usually cures HCV – regardless of HIV status. However, patents and…

Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the roundtable session “Challenging unmerited patents.”

Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the parallel session “Preventing bad patents: The role of patent examination.”

Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the plenary session “The role of civil society in the TRIPS flexibilities implementation.”

In 2011, Congress passed the Leahy-Smith America Invents Act (“AIA”) to curb the spread of unmerited patents, stop abusive litigation, and ensure a fair playing field for patent applicants. Leahy-Smith America Invents Act, Pub. L. No. 112- 20, 125 Stat. 284, 35 U.S.C. § 1 et seq. (2011). In the face of industry overreliance on…

The American health system is poised to incur $55 billion in excess costs from pharmaceutical companies’ strategies to delay competition on three drugs

With the majority of voters on both sides of the aisle saying Congress’s top priority should be lowering high drug costs, an upcoming U.S. Supreme Court case could significantly hamper the country’s ability to lower the price of medicine and assess and remove unmerited pharmaceutical patents. This policy brief examines the little-discussed health implications of…

“Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” was a meeting held on July 18, 2017 to provide the public an opportunity to submit comments concerning administration of the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) to help ensure the intended balance between encouraging innovation in drug…